New player joins PBC market

Posted 1 April 2025 PM 

Ipsen is looking to join Chiesi and Dr Falk Pharma in the primary biliary cholangitis (PBC) market with its new treatment option Iqirvo approved by the TGA last month.

The TGA nod is a promising sign for Iqirvo’s reimbursement prospects with Ipsen awaiting the PBAC’s decision from the March meeting where it was considered for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as a monotherapy in adults unable to tolerate UDCA.

To see the whole article, please login